1,375 results match your criteria Congestive Heart Failure Surgical Options


Continuous-Flow Left Ventricular Assist Devices and the Aortic Valve: Interactions, Issues, and Surgical Therapy.

Curr Heart Fail Rep 2020 Jun 3. Epub 2020 Jun 3.

Division of Cardiac Surgery, Department of Surgery, Wexner Medical Center Ohio State University, Columbus, OH, USA.

Purpose Of Review: Concomitant valve disease is common in patients undergoing continuous-flow left ventricular assist device (CF-LVAD) implantation. In this review, we characterize the epidemiology and management of aortic valve disease following CF-LVAD.

Recent Findings: Studies suggest that 20-40% of patients have mild or greater aortic insufficiency (AI) at baseline and that AI progresses following CF-LVAD implantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11897-020-00464-0DOI Listing

Atrioventricular Valve Regurgitation in Single Ventricle Heart Disease: A Common Problem Associated With Progressive Deterioration and Mortality.

J Am Heart Assoc 2020 Jun 16;9(11):e015737. Epub 2020 May 16.

Department of Pediatrics The Heart Institute Cincinnati Children's Hospital Medical Center University of Cincinnati College of Medicine Cincinnati OH.

The Fontan procedure has provided patients with single ventricle physiology extended survival into adulthood and in many cases has improved their quality of life. Atrioventricular valve regurgitation (AVVR) is common in single ventricle patients and is associated with increased risk of mortality. AVVR is more common in patients with a systemic tricuspid or common atrioventricular valve but is generally progressive irrespective of underlying valve morphology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/JAHA.119.015737DOI Listing

New developments in transcatheter therapy of mitral valve disease.

J Thorac Dis 2020 Apr;12(4):1728-1739

Department of Cardiothoracic Surgery, The University of Frankfurt, Frankfurt, Germany.

Mitral valve regurgitation (MR) belongs to one of the most common acquired valve diseases in western countries with increasing prevalence in older age. For patients with high perioperative risk and older age prohibitive for valve surgery, the development of transcatheter mitral valve therapies offers new options. Assessment of the severity and etiology of MR and thorough imaging of the mitral valve anatomy and pathology are necessary prerequisites for appropriate decision making in the field of transcatheter mitral valve therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2019.12.137DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212154PMC

Catheter and Surgical Therapies for Right Heart Failure: Current and Future Options.

Semin Thorac Cardiovasc Surg 2020 May 3. Epub 2020 May 3.

Heart and Vascular Institute, Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio. Electronic address:

The objective of this review is to describe the various support options available for the failing right heart with a focus on stabilization using assist devices. Right heart failure has multiple etiologies and is a strong and independent predictor of mortality and poor clinical outcomes. Early intervention with catheter and surgical-based mechanical circulatory support can stabilize the critically ill patient and allow for right ventricular recovery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semtcvs.2020.02.034DOI Listing

Molecular Approaches in Single Ventricle Management.

Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2020 ;23:77-85

Division of Cardiac Surgery, Department of Surgery, University of Southern California, Los Angeles, California; Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California; Heart Institute, Children's Hospital, Los Angeles, Los Angeles, California. Electronic address:

Advances in medical and surgical management have significantly improved early outcomes in single ventricle congenital heart disease over the last 2 decades. Despite these advances, long-term outcomes remain suboptimal and therapeutic options to address systemic ventricular and/or Fontan failure are limited even in the modern era. Intricate molecular biologic techniques have shed light into the mechanisms of development of single ventricle disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.pcsu.2020.03.003DOI Listing
January 2020

Translational large animal model of hibernating myocardium: characterization by serial multimodal imaging.

Basic Res Cardiol 2020 Apr 14;115(3):33. Epub 2020 Apr 14.

Translational Laboratory for Cardiovascular Imaging and Therapy, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), C/ Melchor Fernandez Almagro 3, Madrid, 28029, Spain.

Nonrevascularizable coronary artery disease is a frequent cause of hibernating myocardium leading to heart failure (HF). Currently, there is a paucity of therapeutic options for patients with this condition. There is a lack of animal models resembling clinical features of hibernating myocardium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00395-020-0788-0DOI Listing
April 2020
5.414 Impact Factor

Pulmonary Hypertension and Right Ventricular Failure: Lung Transplant Versus Heart-Lung Transplant.

Cardiol Clin 2020 May 28;38(2):269-281. Epub 2020 Feb 28.

Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, 1161 21st Avenue South, T1218 MCN, Nashville, TN, USA.

Pulmonary arterial hypertension is a highly morbid disease with limited treatment options that improve survival and currently the only curative treatment is transplantation. There is a small body of literature comparing the efficacy of lung and heart-lung transplantation in this population. The bulk of evidence suggests that most patients with severe right ventricular failure undergoing transplant will have recovery of right ventricular function after lung transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccl.2020.01.002DOI Listing

Right Heart Failure After Left Ventricular Assist Device Placement: Medical and Surgical Management Considerations.

Authors:
Francis D Pagani

Cardiol Clin 2020 May 28;38(2):227-238. Epub 2020 Feb 28.

Department of Cardiac Surgery, Center for Circulatory Support, Frankel Cardiovascular Center, University of Michigan, 5161 Cardiovascular Center, SPC 5864, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA. Electronic address:

Durable left ventricular assist device therapy is an increasingly accepted surgical therapy for advanced heart failure refractory to guideline-directed medical therapy. Right heart failure is a known and frequent complication after durable left ventricular assist device implantation and remains an important clinical challenge. Medical management of right heart failure after left ventricular assist device therapy focuses on improving right ventricular contractility and optimizing right ventricular preload and afterload. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccl.2020.01.005DOI Listing

Multi-Band Surgery for Repaired Tetralogy of Fallot Patients With Reduced Right Ventricle Ejection Fraction: A Pilot Study.

Front Physiol 2020 19;11:198. Epub 2020 Mar 19.

School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.

Introduction: Right ventricle (RV) failure is one of the most common symptoms among patients with repaired tetralogy of Fallot (TOF). The current surgery treatment approach including pulmonary valve replacement (PVR) showed mixed post-surgery outcomes. A novel PVR surgical strategy using active contracting bands is proposed to improve the post-PVR outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphys.2020.00198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103653PMC

Management of ventricular arrhythmias in patients with LVAD.

Curr Opin Cardiol 2020 May;35(3):289-294

Department of Internal Medicine, Section on Cardiovascular Medicine, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA.

Purpose Of Review: Left ventricular assist devices (LVADs) have extended the life expectancy of patients with heart failure. The hemodynamic support afforded by LVADs in this population has also resulted in patients having prolonged ventricular arrhythmias. The purpose of this article is to review the mechanisms of ventricular arrhythmias in LVADs and the available management strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HCO.0000000000000730DOI Listing

Parachute mitral valve: Morphology and surgical management.

Authors:
Shi-Min Yuan

Turk Gogus Kalp Damar Cerrahisi Derg 2020 Jan 23;28(1):219-226. Epub 2020 Jan 23.

Department of Cardiothoracic Surgery, The First Hospital of Putian, Teaching Hospital, Fujian Medical University, Putian, China.

Background: This review aims to discuss morphology and surgical management of parachute mitral valve.

Methods: A total of 62 articles in the English language with 330 parachute mitral valve patients were retrieved from the PubMed, HighWire Press, and Cochrane Library databases using specific MeSH terms and keywords between January 2000 and December 2018. In these articles, morphology of parachute mitral valve and surgical treatment options were investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5606/tgkdc.dergisi.2020.18041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067029PMC
January 2020

Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP).

Nutr Res Rev 2020 Mar 16:1-25. Epub 2020 Mar 16.

Department of Hypertension, Medical University of Lodz, Lodz, Poland.

Heart failure (HF) is a complex clinical syndrome that represents a major cause of morbidity and mortality in Western countries. Several nutraceuticals have shown interesting clinical results in HF prevention as well as in the treatment of the early stages of the disease, alone or in combination with pharmacological therapy. The aim of the present expert opinion position paper is to summarise the available clinical evidence on the role of phytochemicals in HF prevention and/or treatment that might be considered in those patients not treated optimally as well as in those with low therapy adherence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S0954422420000049DOI Listing

Percutaneous pulmonary valve implantation based on minimally invasive direct coronary bypass surgery.

Ann Thorac Surg 2020 Mar 4. Epub 2020 Mar 4.

Department of Children and Adolescent Medicine, Pediatric cardiology, Frankfurt University Hospital, Frankfurt am Main, Germany.

Approximately 5% of percutaneous pulmonary valve implantation are at risk for coronary compression. Therefore, PPVI is contra-indicated if coronary anomalies and tested coronary flow impairment are observed. Simultaneous right ventricular outflow tract ballooning and coronary angiography are mandatory elucidating contraindications for PPVI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2020.01.062DOI Listing

A case report: metastasis of melanoma to the heart in an era of immunotherapy.

Eur Heart J Case Rep 2019 Dec 26;3(4):1-7. Epub 2019 Oct 26.

Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus, Denmark.

Background: Cardiac metastasis of melanoma rarely causes heart failure symptoms and the recognition of cardiac involvement is in most cases first established post-mortem. Surgical removal might be considered in selected cases in patients with an inflow or outflow tract obstruction even though the survival remains poor. Frequently, the metastasis cannot be removed and therapeutic options include conventional chemotherapy or immunotherapy, which is currently recommended as first-line treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ehjcr/ytz182DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042148PMC
December 2019

Surgical mitral valve replacement using direct implantation of Sapien 3 valve in a patients with severe mitral annular calcification without adjunctive techniques, a case report.

J Cardiothorac Surg 2020 Feb 24;15(1):42. Epub 2020 Feb 24.

Cardiac Sciences Department, King Fahad Cardiac Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Background: Mitral annular calcification (MAC) occurs represents a challenge to surgeons during mitral valve (MV) surgery with increased perioperative risk.

Case Presentation: We describe a challenging case of an elderly female patient with multiple comorbidities who presented with symptoms and signs of heart failure with a previous history of mechanical aortic valve replacement 15 years prior to presentation. Echocardiogram showed severe mitral stenosis and regurgitation with severe calcification of the mitral annulus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13019-020-1083-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041179PMC
February 2020

Atrial fibrillation surgery with a focus on patients with reduced left ventricular function and heart failure.

Europace 2020 Apr;22(4):517-521

Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Martinistr. 52, 20246 Hamburg, Germany.

This review article aims to give an overview on the different surgical treatment options for atrial fibrillation It includes concomitant- as well as stand-alone surgical ablation therapy and outlines the main issues in patients with heart failure and reduced LVEF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/europace/euaa016DOI Listing

Impending paradoxical embolism: about two cases. 3D echocardiographic imaging and discussion of treatment options.

Acta Chir Belg 2020 Feb 17:1-4. Epub 2020 Feb 17.

Department of Cardiology, CHU Marie Curie, Charleroi, Belgium.

Impending paradoxical embolism (IPDE) is a rare condition where a thrombus straddles the foramen ovale with a high risk of arterial embolism. We report two cases of impending paradoxical embolism, an uncommon condition with a high mortality rate. The first in a young woman with acute right heart failure operated emergently, the second, in an old and frail lady presenting an ischemia of the left arm, treated by anticoagulants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00015458.2020.1728910DOI Listing
February 2020

Acute management of ventricular tachycardia.

Herzschrittmacherther Elektrophysiol 2020 Mar 6;31(1):26-32. Epub 2020 Feb 6.

Klinik für Interventionelle Elektrophysiologie, Rhön-Klinikum Campus Bad Neustadt, Von-Guttenberg-Str. 11, 97616, Bad Neustadt a. d. Saale, Germany.

Acute management of patients with ventricular arrhythmia (VA) is aimed at immediate VA termination if the patient is hemodynamically instable and early termination after initial diagnostic work-up if tolerated. Prolonged episodes of VA may lead to hemodynamic and metabolic decompensation and early resumption of normal ventricular activation is warranted. Termination is best performed by electrical cardioversion, anti-tachycardia pacing (if available, in cases with an implanted defibrillator [ICD]) or defibrillation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00399-020-00664-0DOI Listing

Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team.

Int J Cardiol 2020 Apr 11;304:86-92. Epub 2020 Jan 11.

Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy.

Patients with hypertrophic cardiomyopathy (HCM) exhibit a variable phenotype with ventricular hypertrophy as the cardinal manifestation and left ventricular (LV) outflow tract obstruction (LVOTO) as a key pathophysiologic determinant. Patients with severe LVOTO usually present with exertional dyspnea, exertional syncope, and heart failure symptoms, while successful relief of LVOTO by pharmacological or invasive interventions leads to a dramatic improvement in clinical status. Proper management of obstructive HCM remains challenging and poses numerous clinical dilemmas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2020.01.021DOI Listing

The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.

Biochem Biophys Res Commun 2020 Mar 21;524(1):50-56. Epub 2020 Jan 21.

Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Division of Vascular Surgery, St. Michael's Hospital, Toronto, ON, Canada; Molecular Medicine Research Laboratories, Robarts Research Institute, London, ON, Canada; Department of Physiology and Pharmacology, Western University, London, ON, Canada.

Pulmonary arterial hypertension (PAH) is a rare, but progressive and devastating vascular disease with few treatment options to prevent the advancement to right ventricular dysfunction hypertrophy and failure. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, enhances urinary glucose excretion as well as reduces cardiovascular events and mortality in individuals with type 2 diabetes. While empagliflozin has been reported to lower systemic hypertension due to increased diuresis, the effect of empagliflozin on PAH is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2020.01.015DOI Listing

Infective endocarditis post-transcatheter aortic valve implantation (TAVI), microbiological profile and clinical outcomes: A systematic review.

PLoS One 2020 17;15(1):e0225077. Epub 2020 Jan 17.

Sharif Medical and Dental College, Lahore, Pakistan.

Background: The data on infective endocarditis after transcatheter aortic valve implantation (TAVI) is scarce and limited to case reports and case series in the literature. It is the need of the hour to analyze the available data on post-TAVI infective endocarditis from the available literature. The objectives of this systematic review were to evaluate the incidence of infective endocarditis after transcatheter aortic valve implantation, its microbiological profile and clinical outcomes. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0225077PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968844PMC
March 2020
3.234 Impact Factor

Current AATS guidelines on surgical treatment of infective endocarditis.

Ann Cardiothorac Surg 2019 Nov;8(6):630-644

Department of Cardiovascular and Thoracic Surgery, Northwell Health/Southside Hospital, Bay Shore, NY, USA.

The 2016 American Association for Thoracic Surgery (AATS) guidelines for surgical treatment of infective endocarditis (IE) are question based and address questions of specific relevance to cardiac surgeons. Clinical scenarios in IE are often complex, requiring prompt diagnosis, early institution of antibiotics, and decision-making related to complications, including risk of embolism and timing of surgery when indicated. The importance of an early, multispecialty team approach to patients with IE is emphasized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/acs.2019.10.05DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892713PMC
November 2019
5 Reads

Managing Mitral Regurgitation in Heart Failure-Perspectives After COAPT.

Curr Treat Options Cardiovasc Med 2019 Dec 10;21(12):86. Epub 2019 Dec 10.

Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.

Purpose Of Review: Functional mitral regurgitation (MR) in setting of cardiomyopathy causes significant morbidity and worsened survival. Surgical therapies have failed to demonstrate significant overall benefit for functional MR. More recently, major trials utilizing transcatheter therapies for functional MR have been completed and offer new avenues for intervention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11936-019-0799-zDOI Listing
December 2019

Heart Failure in Adult Congenital Heart Disease: From Advanced Therapies to End-of-Life Care.

Can J Cardiol 2019 Dec 26;35(12):1723-1739. Epub 2019 Jul 26.

Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; The Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, Ontario, Canada. Electronic address:

There is mounting recognition that some of the most urgent problems of adult congenital heart disease (ACHD) are the prevention, diagnosis, and management of heart failure (HF). Recent expert consensus and position statements not only emphasize a specific and pressing need to tackle HF in ACHD (ACHD-HF) but also highlight the difficulty of doing so given a current sparsity of data. Some of the challenges will be addressed by this review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cjca.2019.07.626DOI Listing
December 2019

Diagnosis and treatment of abnormal left coronary artery originating from the pulmonary artery: A single-center experience.

Anatol J Cardiol 2019 Nov;22(6):325-331

Department of Pediatric Cardiovascular Surgery, Faculty of Medicine, Başkent University; Ankara-Turkey.

Objective: We aimed to review symptoms, findings, surgical treatment options, short- and mid-term outcomes, and reoperation rate of patients diagnosed with of left coronary artery from the pulmonary artery (ALCAPA) of an anomalous origin in our institution.

Methods: From May 2000 to March 2018, 33 patients who had left coronary artery originating from the pulmonary artery were retrospectively examined. The clinical features of patients, diagnostic tools and their efficacy, outcomes of surgical repair, and problems during follow-up were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14744/AnatolJCardiol.2019.30670DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955047PMC
November 2019

Pediatric ventricular assist devices: what are the key considerations and requirements?

Expert Rev Med Devices 2020 Jan 31;17(1):57-74. Epub 2019 Dec 31.

Department of Cardiothoracic and Vascular Surgery, Cardio Centrum Berlin, Berlin, Germany.

: The development of ventricular assist devices (VADs) have enabled myocardial recovery and improved patient survival until heart transplantation. However, device options remain limited for children and lag in development.: This review focuses on the evolution of pediatric VADs in becoming to be an accepted treatment option in advanced heart failure, discusses the classification of VADs available for children, i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17434440.2020.1699404DOI Listing
January 2020

Combating Donor Organ Shortage: Organ Care System Prolonging Organ Storage Time and Improving the Outcome of Heart Transplantations.

Cardiovasc Ther 2019 1;2019:9482797. Epub 2019 Apr 1.

Faculty of Medicine, Tarumanagara University, Jl. Letjen S. Parman No. 1, West Jakarta, Indonesia.

Introduction: Cardiovascular diseases are the number one cause of death globally contributing to 37% of all global deaths. A common complication of cardiovascular disease is heart failure, where, in such cases, the only solution would be to conduct a heart transplant. Every 10 minutes a new patient is added to the transplant waiting list. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/9482797DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739795PMC

Meta-Analysis of Atrial Fibrillation Ablation in Patients with Systolic Heart Failure.

Cardiovasc Ther 2019 6;2019:8181657. Epub 2019 Jan 6.

Michigan State University, McLaren Greater Lansing, MI, USA.

Atrial fibrillation (AF) and heart failure (HF) are two common conditions that often coexist and predispose each to one another. AF increases hospitalization rates and overall mortality in patients with HF. The current available therapeutic options for AF in patients with HF are diverse and guidelines do not provide a clear consensus regarding the best management approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8181657DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739791PMC

Endomyocardial Fibrosis: an Update After 70 Years.

Curr Cardiol Rep 2019 11 22;21(11):148. Epub 2019 Nov 22.

Imperial College London, London, UK.

Purpose Of Review: This review aims at highlighting the need to better understand the pathogenesis and natural history of endomyocardial fibrosis when set against its changing endemicity and disease burden, improvements in diagnosis, and new options for clinical management.

Recent Findings: Progress in imaging diagnostic techniques and availability of new targets for drug and surgical treatment of heart failure are contributing to earlier diagnosis and may lead to improvement in patient survival. Endomyocardial fibrosis was first described in Uganda by Davies more than 70 years ago (1948). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11886-019-1244-3DOI Listing
November 2019

Vasoresponsiveness in patients with heart failure (VASOR): protocol for a prospective observational study.

J Cardiothorac Surg 2019 Nov 21;14(1):200. Epub 2019 Nov 21.

Department of Cardiothoracic Surgery, Leiden University Medical Center, PO Box 9600, Leiden, 2300 RC, The Netherlands.

Background: Vasoplegia is a severe complication which may occur after cardiac surgery, particularly in patients with heart failure. It is a result of activation of vasodilator pathways, inactivation of vasoconstrictor pathways and the resistance to vasopressors. However, the precise etiology remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13019-019-1014-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868831PMC
November 2019

Stem Cells: The Game Changers of Human Cardiac Disease Modelling and Regenerative Medicine.

Int J Mol Sci 2019 Nov 16;20(22). Epub 2019 Nov 16.

Department of Experimental and Clinical Medicine, Research Center for Advanced Biochemistry and Molecular Biology, University "Magna Graecia" of Catanzaro, 88100 Loc., Germaneto, Catanzaro, Italy.

A comprehensive understanding of the molecular basis and mechanisms underlying cardiac diseases is mandatory for the development of new and effective therapeutic strategies. The lack of appropriate cell models that faithfully mirror the human disease phenotypes has hampered the understanding of molecular insights responsible of heart injury and disease development. Over the past decade, important scientific advances have revolutionized the field of stem cell biology through the remarkable discovery of reprogramming somatic cells into induced pluripotent stem cells (iPSCs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20225760DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888119PMC
November 2019

Paravalvular Leaks-From Diagnosis to Management.

Curr Treat Options Cardiovasc Med 2019 Nov 14;21(11):67. Epub 2019 Nov 14.

Cardiac Ultrasound Laboratory, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Yawkey 5B, Boston, MA, 02114, USA.

Purpose Of Review: As the number of surgical and transcatheter valve replacements continue to increase in the aging population, so does the incidence of paravalvular leak (PVL). Given its impact on morbidity and mortality, this article will focus on the epidemiology, clinical presentation, diagnostic assessment, and available treatments for PVL.

Recent Findings: Despite being performed on inoperable and typically higher risk patients, short-term complication rates of transcatheter PVL closure appear relatively low (< 10%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11936-019-0776-6DOI Listing
November 2019

[Atrial fibrillation : Recent studies and new treatment options].

Herzschrittmacherther Elektrophysiol 2019 Dec 13;30(4):356-362. Epub 2019 Nov 13.

Klinik für Elektrophysiologie und Rhythmologie, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Deutschland.

Catheter ablation by pulmonary vein isolation (PVI) is established in patients suffering from drug-refractory symptomatic atrial fibrillation (AF). According to recent guidelines, it can also be offered to AF patients as a first-line treatment. The CASTLE-AF study randomized AF patients with severely impaired left ventricular (LV) function to catheter ablation or drug therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00399-019-00657-8DOI Listing
December 2019

Mapping and Ablation of Ventricular Arrhythmias in Cardiomyopathies.

Card Electrophysiol Clin 2019 12;11(4):635-655

Department of Cardiology, Huashan Hospital Fudan University, No.12 Wulumuqizhong Road, Shanghai 200040, China.

Mapping and ablation of ventricular arrhythmias in patients with nonischemic cardiomyopathies remain a major challenge. The electroanatomic abnormalities are frequently inaccessible to conventional endocardial ablations. Diagnostic diligence with a thorough understanding of the potential mechanisms/substrate, coupled with detailed electroanatomic mapping, is essential. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccep.2019.08.005DOI Listing
December 2019

Advanced Heart Failure Therapies for Adults With Congenital Heart Disease: JACC State-of-the-Art Review.

J Am Coll Cardiol 2019 11;74(18):2295-2312

Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts.

In the contemporary era, nearly 85% of children with congenital heart disease will reach adulthood. Despite optimal medical and surgical treatment, many will experience a progressive decline in cardiopulmonary function leading to advanced heart failure. These patients present unique anatomic and physiological challenges to the care team, and unlike adults with acquired heart disease who progress to severe heart failure, advanced treatment options such as mechanical circulatory support and cardiac transplant may be limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.09.004DOI Listing
November 2019
1 Read

Poor Outcome of Surgical Management of Acute Malfunctioning Mechanical Mitral Valve During Pregnancy. Should Centers with Limited Resources Find Different Options?

Heart Surg Forum 2019 Sep 26;22(5):E405-E410. Epub 2019 Sep 26.

Sohag University Hospital and Faculty of Medicine, Sohag Governorate, Egypt.

Background: Rheumatic heart disease (RHD) is the most common cardiac disease in pregnancy in developing countries with the mitral valve being the most affected. In this study, the results of surgical intervention in pregnant women presented with acute malfunctioning mechanical mitral valve were discussed.

Methods: All patients underwent emergency redo mitral valve replacement due to acute malfunctioning mechanical mitral valve during pregnancy in a single center between January 2005 and December 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1532/hsf.2497DOI Listing
September 2019
2 Reads
0.562 Impact Factor

Mitral valve repair after failed MitraClip therapy.

Multimed Man Cardiothorac Surg 2019 Sep 30;2019. Epub 2019 Sep 30.

Department of Cardiothoracic Surgery Maastricht University Medical Center Maastricht The Netherlands.

Although the long-term durability of transcatheter procedures has yet to be established, their emergence as an option for mitral valve repair seems to have provided the surgical community with another tool in the toolbox for treatment of mitral valve disease.  Edge-to-edge mitral valve repair (with the MitraClip, Abbott, Abbott Park, IL, USA) was developed as a novel procedure, based on Alfieri's technique, in which the repair can be performed through a percutaneous approach for correction of mitral valve regurgitation. However, with new treatment options, new complications are unavoidable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1510/mmcts.2019.027DOI Listing
September 2019
1 Read

Functional Mitral Regurgitation in Heart Failure.

Cardiol Rev 2019 Nov/Dec;27(6):327-336

From the Division of Cardiology, Weill Cornell Medical College - New York Presbyterian Hospital, New York, NY.

Functional mitral regurgitation (FMR) in the setting of left ventricular (LV) dysfunction and heart failure portends a poor prognosis. Guideline-directed medical therapy remains the cornerstone of initial treatment, with emphasis placed on treatment of the underlying LV dysfunction, as FMR is a secondary phenomenon and a disease due to LV remodeling. Surgical correction of FMR is controversial because it typically does not address the underlying mechanism and etiology of the condition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000269DOI Listing
February 2020
3 Reads

Dilated cardiomyopathy in children: moving beyond traditional pharmacologic therapy.

Curr Opin Cardiol 2020 Jan;35(1):52-57

Division of Pediatric Cardiology, University of Miami Miller School of Medicine, Miami, Florida, USA.

Purpose Of Review: Dilated cardiomyopathy (DCM) is a rare myocardial disorder characterized by a dilated left ventricle and systolic dysfunction. Globally, it affects around 1 in every 100 000 children. The prognosis is generally poor, with 40% either failing traditional medical therapy within the first 2 years or requiring a heart transplant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HCO.0000000000000692DOI Listing
January 2020
4 Reads

Left atrial myxoma: an unusual cause of postpartum tachycardia and shortness of breath.

BMJ Case Rep 2019 Sep 16;12(9). Epub 2019 Sep 16.

Department of Cardiology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.

Primary cardiac tumours are exceedingly rare in clinical practice and a myxoma is certainly not the first suspected diagnosis on a list of differentials in a patient presenting with breathlessness and tachycardia. Naturally, a structured work-up to rule out much more common conditions will take place. Nonetheless, an index of clinical suspicion is required especially when a clear-cut diagnosis is not forthcoming. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-231283DOI Listing
September 2019
2 Reads

Pulmonary Hypertension in Patients Eligible for Transcatheter Mitral Valve Repair: Prognostic Impact and Clinical Implications.

Curr Treat Options Cardiovasc Med 2019 Sep 10;21(10):60. Epub 2019 Sep 10.

Cardiac Ultrasound Laboratory, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, Yawkey 5E, Boston, MA, 02114, USA.

Purpose Of Review: Transcatheter edge-to-edge mitral valve repair (TMVr) has been increasingly used in the treatment of patients with severe symptomatic mitral regurgitation who are at high or prohibitive risk for surgical intervention. Pre-existing pulmonary hypertension is known to pertain worse prognosis for patients who are undergoing surgical intervention. The aim of this review is to discuss the current literature on the effects of pulmonary hypertension on the transcatheter edge-to-edge mitral valve repair outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11936-019-0768-6DOI Listing
September 2019
2 Reads

Management of valvulopathies with acute severe heart failure and cardiogenic shock.

Arch Cardiovasc Dis 2019 Dec 3;112(12):773-780. Epub 2019 Sep 3.

Cardiology Department, Montpellier University Hospital, 34295 Montpellier, France; Inserm U1046, CNRS UMR 9214, PhyMedExp, 34090 Montpellier, France.

Cardiogenic shock is a critical clinical situation, requiring rapid diagnosis, aetiological assessment and immediate initiation of therapy. In industrialized countries, aortic stenosis is the most frequent left-sided valvulopathy, followed by mitral regurgitation, aortic regurgitation and mitral stenosis. Severe valvulopathies leading to cardiogenic shock are not rare conditions, but few data are available on their optimal management. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18752136193014
Publisher Site
http://dx.doi.org/10.1016/j.acvd.2019.06.009DOI Listing
December 2019
2 Reads

Morbid Obesity as a Therapeutic Target for Heart Failure.

Curr Treat Options Cardiovasc Med 2019 Sep 5;21(10):52. Epub 2019 Sep 5.

Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Desk J3-4, Cleveland, OH, 44195, USA.

Purpose Of Review: This review will define morbid obesity and relationship between morbid obesity and heart failure syndromes. It will delve into unique challenges facing patients with dual diagnoses of heart failure and morbid obesity and examine the data that obesity should be a target in the treatment of heart failure.

Recent Findings: Emerging literature has indicated the safety and efficacy of surgical weight loss in patients with heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11936-019-0754-zDOI Listing
September 2019
2 Reads

Elevated admission glucose is common and associated with high short-term complication burden after acute myocardial infarction: Insights from the VALIDATE-SWEDEHEART study.

Diab Vasc Dis Res 2019 11 3;16(6):582-584. Epub 2019 Sep 3.

Cardiology Unit, Department of Medicine K2, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, Sweden.

Objective: To investigate the association between admission plasma glucose and cardiovascular events in patients with acute myocardial infarction treated with modern therapies including early percutaneous coronary intervention and modern stents.

Methods: Patients ( = 5309) with established diabetes and patients without previously known diabetes with a reported admission plasma glucose, included in the VALIDATE trial 2014-2016, were followed for cardiovascular events (first of mortality, myocardial infarction, stroke, heart failure) within 180 days. Event rates were analysed by four glucose categories according to the World Health Organization criteria for hyperglycaemia and definition of diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1479164119871540DOI Listing
November 2019
1 Read

The Choice of Treatment in Ischemic Mitral Regurgitation With Reduced Left Ventricular Function.

Ann Thorac Surg 2019 12 22;108(6):1901-1912. Epub 2019 Aug 22.

Department of Surgery and Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York, New York.

Background: Ischemic mitral regurgitation is a condition characterized by mitral insufficiency secondary to an ischemic left ventricle. Primarily, the pathology is the result of perturbation of normal regional left ventricular geometry combined with adverse remodeling. We present a comprehensive review of contemporary surgical, medical, and percutaneous treatment options for ischemic mitral regurgitation, rigorously examined by current guidelines and literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2019.06.039DOI Listing
December 2019
3 Reads

Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options.

Heart Fail Rev 2020 Mar;25(2):295-303

Department of Medical, Surgical, Neurological, Aging and Metabolic Sciences, University "L. Vanvitelli", Naples and Institute of Diagnostic and Nuclear Development (SDN), IRCCS, Naples, Italy.

Transition from stage C to stage D of heart failure (HF) represents an irreversible process toward end-stage disease. Crucial interventions to be adopted in the attempt to interfere with this process are represented by the identification of patients at high risk to develop HF progression and by an effective and prompt management. Markers of worse prognosis and disease progression are well established and include recurrence of HF decompensation, intolerance to the neurohormonal standard pharmacological treatment, and resistance to loop diuretics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-019-09823-zDOI Listing
March 2020
2 Reads

Caring for Patients With Ventricular Assist Devices: A Mini-Review of the Literature.

Transplant Proc 2019 Sep 9;51(7):2492-2494. Epub 2019 Aug 9.

Department of Cardiovascular Surgery, University of Health Sciences Ankara City Hospital, Ankara, Turkey.

Heart transplantation, one of the treatment options for end-stage heart failure, is still regarded as the gold standard treatment to improve quality and length of life. However, the rapid increase in the number of patients waiting for heart transplantation and the inadequate number of donors makes heart transplantation a less feasible option and increases the need for ventricular assist devices as an alternative. The success of ventricular assist device implantation requires the collaboration of a multidisciplinary team consisting of cardiac surgeons, nurses, ventricular assist device coordinators, cardiologist, cardiac anesthesia specialists, perfusionists, and physiotherapists. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2019.03.046DOI Listing
September 2019
3 Reads

Dural sinus malformation with giant pouch (DSMGP): symptoms and treatment.

Childs Nerv Syst 2020 Feb 8;36(2):343-348. Epub 2019 Aug 8.

Department of Neurosurgery, Hospital Nacional de Pediatria JP Garrahan, Combate de los Pozos 1881, 1254, Buenos Aires, Argentina.

Objective: The aim of this study is to describe the clinical manifestations and treatment options of patients having dural sinus malformation with giant pouch (DSMGP) in a tertiary pediatric center.

Introduction: Dural sinus malformation with giant pouch (DSMGP) is a rare vascular malformation affecting fetuses, newborns, and infants. It is characterized by a dilated dural sinus frequently thrombosed with arteriovenous fistula (AVF) in its wall. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00381-019-04338-2DOI Listing
February 2020
3 Reads

Hurdles to Cardioprotection in the Critically Ill.

Int J Mol Sci 2019 Aug 5;20(15). Epub 2019 Aug 5.

Critical Care Research Group, The Prince Charles Hospital, Chermside 4032, Australia.

Cardiovascular disease is the largest contributor to worldwide mortality, and the deleterious impact of heart failure (HF) is projected to grow exponentially in the future. As heart transplantation (HTx) is the only effective treatment for end-stage HF, development of mechanical circulatory support (MCS) technology has unveiled additional therapeutic options for refractory cardiac disease. Unfortunately, despite both MCS and HTx being quintessential treatments for significant cardiac impairment, associated morbidity and mortality remain high. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20153823DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695809PMC
August 2019
7 Reads

Abdominal Surgery With Bilateral Rectus Sheath Block: A Case Report.

A A Pract 2019 Oct;13(7):278-280

From the Department of Anesthesiology, Emory University Hospital, Emory University School of Medicine, Atlanta, Georgia.

A 44-year-old man, American Society of Anesthesiologists physical status class IV, presented for fulguration of anal condyloma and diverting colostomy. The patient's medical history includes World Health Organization (WHO) class I pulmonary hypertension (PH), right heart failure, and bilateral lower extremity paralysis due to Pott's disease. The patient was not a candidate for neuraxial anesthesia due to sacral decubitus ulcers, and alternative options to general anesthesia (GA) were considered to avoid the high risk of right ventricular (RV) failure and ensuing complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1213/XAA.0000000000001055DOI Listing
October 2019
2 Reads